Mechanisms of disease: Histone modifications in Huntington's disease

Nature Clinical Practice Neurology

Volumn 2, Issue 6, 2006, Pages 330-338

  Sadri Vakili, Ghazaleh ^a   Cha, Jang Ho J ^b  

^a MassGeneral Institute for Neurodegenerative Disease   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chromatin; Histone deacetylase inhibitors; Histones; Huntington's disease; Transcription

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; POLYGLUTAMINE; TRICHOSTATIN A; VORINOSTAT;

ACETYLATION; AUTOSOMAL DOMINANT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG TARGETING; ENZYME ACTIVITY; EUKARYOTE; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; TRANSCRIPTION REGULATION;

HISTONES; HUMANS; HUNTINGTON DISEASE; TRANSCRIPTION, GENETIC;

EID: 33744504676     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0199     Document Type: Review

References (73)

1. Bates G et al. (Eds; 2002) Huntington's Disease. New York: Oxford University Press
2. Vonsattel JP and DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369-384
3. Beal MF et al. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171
4. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a tdnucleotide repeat that is unstable in Huntington's disease chromosomes. Cell 72: 971-983
5. Duyao MP et al. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387-392
6. Paulson HL and Fischbeck KH (1996) Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 19: 79-107
7. DiFiglia M (1990) Excitotoxic injury of the neostriatum: A model for Huntington's disease. Trends Neurosci 13: 286-289
8. Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta Bio Energetics 1366: 211-223
9. Ona VO et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399: 263-267
10. Wellington CL et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158-9167
11. Goffredo D et al. (2002) Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J Biol Chem 277: 39594-39598
12. Qin ZH et al. (2003) Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 12: 3231-3244
13. Ravikumar B et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585-595
14. Bence NF et al. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555
15. Venkatraman P et al. (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14: 95-104
16. Lunkes A et al. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259-269
17. Davies SW et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548
18. Ross CA et al. (2003) Polyglutamine fibrillogenesis: The pathway unfolds. Proc Natl Acad Sci USA 100: 1-3
19. Colby DW et al. (2004) Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 101: 17616-17621
20. Gidalevitz T et al. (2006) Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311: 1471-1474
21. Kegel KB et al. (2000) Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 20: 7268-7278
22. Cha J-HJ (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23: 387-392
23. Sugars KL and Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19: 233-238
24. Luthi-Carter R and Cha J-H J (2003) Mechanisms of transcriptional dysregulation in Huntington's disease. Clin Neurosci Res 3: 165-177
25. Gerber H-P et al. (1994) Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263: 808-811
26. Karlin S and Burge C (1996) Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development. Proc Natl Acad Sci USA 93: 1560-1565
27. Steffan JS et al. (2000) The Huntington's disease protein interacts with p53 and CBP and represses transcription. Proc Natl Acad Sci USA 97: 6763-6768
28. Nucifora FC Jr et al. (2001) Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291: 2423-2428
29. Huang CC et al. (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 24: 217-233
30. Dunah AW et al. (2002) Sp1 and TAFII 130 transcriptional activity disrupted in early Huntington's disease. Science 296: 2238-2243
31. Augood SJ et al. (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 42: 215-221
32. Cha J-HJ et al. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95: 6480-6485
33. Yohrling GJ and Cha J-HJ (2002) Neurochemistry of Huntington's Disease. In Huntington's Disease, 276-308 (Eds Bates GP et al.) London: Oxford Medical Publications
34. Mangiarini L et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506
35. Weeks RA et al. (1996) Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 40: 49-54
36. A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97: 505-519
37. Luthi-Carter R et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9: 1259-1271
38. Bibb JA et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 97: 6809-6814
39. Hu H et al. (2004) Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20: 3351-3363
40. McCaw EA et al. (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271: 4909-4920
41. Luthi-Carter R et al. (2002) Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 11: 1927-1937
42. Chan EYW et al. (2002) Increased huntingin protein length reduces the severity of polyglutamine-induced gene expression changes in mouse models of Huntington disease. Hum Mol Genet 11: 1939-1951
43. Schaffar G et al. (2004) Cellular toxicity of polyglutamine expansion proteins: Mechanism of transcription factor deactivation. Mol Cell 15: 95-105
44. Zhai W et al. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123: 1241-1253
45. Palhan VB et al. (2005) Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci USA 102: 8472-8477
46. Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403: 41-45
47. Marks PA et al. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483
48. Davis PK and Brackmann RK (2003) Chromatin remodeling and cancer. Cancer Biol Ther 2: 22-29
49. Yasui W et al. (2003) Histone acetylation and gastrointestinal carcinogenesis. Ann NY Acad Sci 983: 220-231
50. Butler LM et al. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7: 962-970
51. Richon VM et al. (2000) Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019
52. Vigushin DM and Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1-13
53. McCampbell A et al. (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 98: 15179-15184
54. Hughes RE et al. (2001) Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci USA 98: 13201-13206
55. Steffan JS et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743
56. Ferrante RJ et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23: 9418-9427
57. Hockly E et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100: 2041-2046
58. Gardian G et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280: 556-563
59. Igarashi S et al. (2003) Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 14: 565-568
60. Hazeki N et al. (2002) Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine. Biochem Biophys Res Commun 294: 429-440
61. Ryu H et al. (2006) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 96: 908
62. Costa E et al. (2002) REELIN and schizophrenia: A disease at the interface of the genome and the epigenome. Mol Interv 2: 47-57
63. Ren M et al. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: Potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89: 1358-1367
64. Villar-Garea A and Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. lnt J Cancer 112: 171-178
65. Jahangeer S et al. (1982) β-adrenergic receptor induction in HeLa cells: Synergistic effect of 5-azacytidine and butyrate. Biochem Biophys Res Commun 108: 1434-1440
66. Marks PA et al. (2003) Histone deacetylases. Curr Opin Pharmacol 3: 344-351
67. Shin HJ et al. (2003) Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22: 3853-3858
68. Dover GJ et al. (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84: 339-343
69. Rubenstein RC and Zeitlin PL (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157: 484-490
70. Hoppe C et al. (1999) Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 62: 221-227
71. Carducci MA et al. (2001) A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7: 3047-3055
72. Gilbert J et al. (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7: 2292-2300
73. Kelly WK et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588